Invion Ltd (IVX) - Total Liabilities
Based on the latest financial reports, Invion Ltd (IVX) has total liabilities worth AU$1.24 Million AUD (≈ $876.08K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IVX operating cash flow to assess how effectively this company generates cash.
Invion Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Invion Ltd's total liabilities have evolved over time, based on quarterly financial data. Check IVX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Invion Ltd Competitors by Total Liabilities
The table below lists competitors of Invion Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Genetic Technologies Ltd
NASDAQ:GENE
|
USA | $4.36 Million |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
USA | $1.13 Billion |
|
Vanquis Banking Group PLC
LSE:VANQ
|
UK | GBX3.01 Billion |
|
C29 Metals Ltd
AU:C29
|
Australia | AU$115.74K |
|
Imagine Lithium Inc
V:ILI
|
Canada | CA$234.08K |
|
PDZ Holdings Bhd
KLSE:6254
|
Malaysia | RM5.48 Million |
|
Aptose Biosciences Inc
TO:APS
|
Canada | CA$25.79 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Invion Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IVX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.69 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Invion Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Invion Ltd (2001–2025)
The table below shows the annual total liabilities of Invion Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.24 Million ≈ $876.08K |
+22.13% |
| 2024-06-30 | AU$1.01 Million ≈ $717.34K |
+55.82% |
| 2023-06-30 | AU$650.62K ≈ $460.36K |
+40.70% |
| 2022-06-30 | AU$462.41K ≈ $327.19K |
-45.69% |
| 2021-06-30 | AU$851.50K ≈ $602.49K |
+160.54% |
| 2020-06-30 | AU$326.82K ≈ $231.25K |
-45.95% |
| 2019-06-30 | AU$604.71K ≈ $427.87K |
-75.24% |
| 2018-06-30 | AU$2.44 Million ≈ $1.73 Million |
+35.35% |
| 2017-06-30 | AU$1.80 Million ≈ $1.28 Million |
-69.89% |
| 2016-06-30 | AU$5.99 Million ≈ $4.24 Million |
-35.13% |
| 2015-06-30 | AU$9.24 Million ≈ $6.54 Million |
+102.10% |
| 2014-06-30 | AU$4.57 Million ≈ $3.23 Million |
-12.33% |
| 2013-06-30 | AU$5.21 Million ≈ $3.69 Million |
+539.38% |
| 2012-06-30 | AU$815.52K ≈ $577.03K |
-88.13% |
| 2011-06-30 | AU$6.87 Million ≈ $4.86 Million |
-25.82% |
| 2010-06-30 | AU$9.26 Million ≈ $6.56 Million |
-23.93% |
| 2009-06-30 | AU$12.18 Million ≈ $8.62 Million |
+88.43% |
| 2008-06-30 | AU$6.46 Million ≈ $4.57 Million |
+113.99% |
| 2007-06-30 | AU$3.02 Million ≈ $2.14 Million |
-66.86% |
| 2006-06-30 | AU$9.11 Million ≈ $6.45 Million |
-22.28% |
| 2005-06-30 | AU$11.73 Million ≈ $8.30 Million |
+505.68% |
| 2004-06-30 | AU$1.94 Million ≈ $1.37 Million |
+26.12% |
| 2003-06-30 | AU$1.53 Million ≈ $1.09 Million |
-11.98% |
| 2002-06-30 | AU$1.74 Million ≈ $1.23 Million |
+24.31% |
| 2001-06-30 | AU$1.40 Million ≈ $992.71K |
-- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more